The ability to isolate, purify and re-inject patient-derived cells with regenerative properties has led to a number of therapeutic products for the treatment of refractory injuries and wounds. Autologous tissue repair is having an impact on a number of areas, including cardiovascular medicine, refractory wound care, orthopedics, and surgical medicine. The potential economic benefits of autologous tissue repair are significant, as an aging population struggles with intractable ailments that historically have required numerous follow-up provider visits. While several autologous therapies require remote processing, the number of therapeutic autologous products that can be processed at the point-of-care is increasing. This report details the autologous tissue repair products and development programs of twenty-seven separate companies in seven countries - companies working to shape the future of tissue regeneration.

Publication Date: June 2006